Arecoline Fundamentals Explained
MI-CP151 was a period 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre analyze to evaluate many intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Most important trial aims had been to evaluate the security and tolerability of sifalimumab in dermatomyositis or polymyosi